July 1, 2020 / 8:02 AM / 12 days ago

BRIEF-Klaria Pharma Holding Launches Clinical Program For Naloxone Alginatefilm Against Opioid Overdose

July 1 (Reuters) - Klaria Pharma Holding AB (publ) :

* LAUNCHES CLINICAL PROGRAM FOR NALOXONE ALGINATEFILM AGAINST OPIOID OVERDOSE

* CLINICAL DOSING STUDY SCHEDULED TO BEGIN DURING 2020

* ESTIMATES THE TOTAL ADDRESSABLE MARKET FOR CO-PRESCRIPTION OF NALOXONE IS WORTH 1.9 BILLION USD IN THE UNITED STATES ALONE

* WE ARE PLANNING TO APPLY FOR MARKET APPROVAL IN EUROPE AND THE UNITED STATES IN 2023 Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below